SKERRATT SARAH ELIZABETH
No ORCID on file
· 304 papers in corpus
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…